ReviewJournal de mycologie medicale2023
Combination therapy in Mucormycosis: Current evidence from the world literature, a mini review.
Review in Journal de mycologie medicale, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 25 citations in OpenAlex.
- Efficacy and safety of amphotericin B colloidal dispersion in the treatment of mucormycosis: a real-world observation.BMC infectious diseases · 2026Observational
- Article
- Antifungal Agents in the 21st Century: Advances, Challenges, and Future Perspectives.Infectious disease reports · 2025Review
- Cutaneous mucormycosis: Unveiling rare manifestations.Journal of family medicine and primary care · 2025Article
- Intra-abdominal Mucormycosis in an Immunocompetent Host: A Rare Presentation and Literature Review.Cureus · 2025Article
- Diagnosis, clinical features, and mortality risk factors in a Chinese cohort with pulmonary mucormycosis.PloS one · 2025Article
- Oral Isavuconazole Combined with Nebulized Inhalation and Bronchoscopic Administration of Amphotericin B for the Treatment of Pulmonary Mucormycosis: A Case Report and Literature Review.Journal of fungi (Basel, Switzerland) · 2024Article
- Breaking the mold: Insights into the clinical management and outcomes of rhinocerebral mucormycosis in adults.IDCases · 2024Article
- A young boy with diabetic ketoacidosis and non-resolving pneumonia.Breathe (Sheffield, England) · 2023Article
- Antifungal Drug Resistance: An Emergent Health Threat.Biomedicines · 2023Review
- Rise of mucormycosis during the COVID-19 pandemic and the challenges faced.Current medical mycology · 2023Review
- Antifungal resistance, combinations and pipeline: oh my!Drugs in context · 2023Review
- Invasive splenic mucormycosis due toFrontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of Mucorales infections is an urgent global public health threat rapidly disseminating during the current COVID-19 pandemic. Invasive mucormycosis carries significant morbidity and mortality; this is further compounded by the lack of newer effective antifungals on the horizon. Liposomal Amphotericin (L-AMB) is currently considered the cornerstone of antifungals therapy against mucormycosis; However, two decades later (since the introduction of L-AMB), the outcome remains dismal. Furthermore, adverse events related to therapeutic doses of L-AMB are also a hindrance. There is an imperative need for an alternative therapeutic approach to reduce the high mortality. One such approach is to combine the amphotericin with other agents (e.g., caspofungin, posaconazole, isavuconazole, and iron chelators) that can work synergistically or help in reducing the therapeutic doses of L-AMB. This review aims to highlight the various treatment approaches by gathering the clinical evidence from the literature and considering all potential pharmacological combinations that can provide the direction for future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.